These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 38193697)

  • 1. Defining the impact of flavivirus envelope protein glycosylation site mutations on sensitivity to broadly neutralizing antibodies.
    Contreras M; Stuart JB; Levoir LM; Belmont L; Goo L
    mBio; 2024 Feb; 15(2):e0304823. PubMed ID: 38193697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dengue Virus Envelope Dimer Epitope Monoclonal Antibodies Isolated from Dengue Patients Are Protective against Zika Virus.
    Swanstrom JA; Plante JA; Plante KS; Young EF; McGowan E; Gallichotte EN; Widman DG; Heise MT; de Silva AM; Baric RS
    mBio; 2016 Jul; 7(4):. PubMed ID: 27435464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigation of the immunogenicity of Zika glycan loop.
    Henderson EA; Tam CC; Cheng LW; Ngono AE; Nguyen AV; Shresta S; McGee M; Padgett H; Grill LK; Martchenko Shilman M
    Virol J; 2020 Mar; 17(1):43. PubMed ID: 32234060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dengue and Zika Virus Domain III-Flagellin Fusion and Glycan-Masking E Antigen for Prime-Boost Immunization.
    Lin HH; Yang SP; Tsai MJ; Lin GC; Wu HC; Wu SC
    Theranostics; 2019; 9(16):4811-4826. PubMed ID: 31367259
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An Envelope-Modified Tetravalent Dengue Virus-Like-Particle Vaccine Has Implications for Flavivirus Vaccine Design.
    Urakami A; Ngwe Tun MM; Moi ML; Sakurai A; Ishikawa M; Kuno S; Ueno R; Morita K; Akahata W
    J Virol; 2017 Dec; 91(23):. PubMed ID: 28956764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of Envelope Protein Antigens To Serologically Differentiate Zika Virus Infection from Dengue Virus Infection.
    Premkumar L; Collins M; Graham S; Liou GA; Lopez CA; Jadi R; Balmaseda A; Brackbill JA; Dietze R; Camacho E; De Silva AD; Giuberti C; Dos Reis HL; Singh T; Heimsath H; Weiskopf D; Sette A; Osorio JE; Permar SR; Miley MJ; Lazear HM; Harris E; de Silva AM
    J Clin Microbiol; 2018 Mar; 56(3):. PubMed ID: 29263206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potent Zika and dengue cross-neutralizing antibodies induced by Zika vaccination in a dengue-experienced donor.
    Dussupt V; Sankhala RS; Gromowski GD; Donofrio G; De La Barrera RA; Larocca RA; Zaky W; Mendez-Rivera L; Choe M; Davidson E; McCracken MK; Brien JD; Abbink P; Bai H; Bryan AL; Bias CH; Berry IM; Botero N; Cook T; Doria-Rose NA; Escuer AGI; Frimpong JA; Geretz A; Hernandez M; Hollidge BS; Jian N; Kabra K; Leggat DJ; Liu J; Pinto AK; Rutvisuttinunt W; Setliff I; Tran U; Townsley S; Doranz BJ; Rolland M; McDermott AB; Georgiev IS; Thomas R; Robb ML; Eckels KH; Barranco E; Koren M; Smith DR; Jarman RG; George SL; Stephenson KE; Barouch DH; Modjarrad K; Michael NL; Joyce MG; Krebs SJ
    Nat Med; 2020 Feb; 26(2):228-235. PubMed ID: 32015557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of Anti-Premembrane Antibody as a Serocomplex-Specific Marker To Discriminate Zika, Dengue, and West Nile Virus Infections.
    Hsieh SC; Tsai WY; Tsai JJ; Stone M; Simmons G; Busch MP; Lanteri M; Stramer SL; Balmaseda A; Harris E; Wang WK
    J Virol; 2021 Sep; 95(19):e0061921. PubMed ID: 34232731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Zika-specific neutralizing antibodies targeting inter-dimer envelope epitopes.
    Sankhala RS; Dussupt V; Donofrio G; Gromowski GD; De La Barrera RA; Larocca RA; Mendez-Rivera L; Lee A; Choe M; Zaky W; Mantus G; Jensen JL; Chen WH; Gohain N; Bai H; McCracken MK; Mason RD; Leggat D; Slike BM; Tran U; Jian N; Abbink P; Peterson R; Mendes EA; Freitas de Oliveira Franca R; Calvet GA; Bispo de Filippis AM; McDermott A; Roederer M; Hernandez M; Albertus A; Davidson E; Doranz BJ; Rolland M; Robb ML; Lynch RM; Barouch DH; Jarman RG; Thomas SJ; Modjarrad K; Michael NL; Krebs SJ; Joyce MG
    Cell Rep; 2023 Aug; 42(8):112942. PubMed ID: 37561630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A conserved set of mutations for stabilizing soluble envelope protein dimers from dengue and Zika viruses to advance the development of subunit vaccines.
    Phan TTN; Hvasta MG; Kudlacek ST; Thiono DJ; Tripathy A; Nicely NI; de Silva AM; Kuhlman B
    J Biol Chem; 2022 Jul; 298(7):102079. PubMed ID: 35643320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prior dengue virus serotype 3 infection modulates subsequent plasmablast responses to Zika virus infection in rhesus macaques.
    Singh T; Miller IG; Venkatayogi S; Webster H; Heimsath HJ; Eudailey JA; Dudley DM; Kumar A; Mangan RJ; Thein A; Aliota MT; Newman CM; Mohns MS; Breitbach ME; Berry M; Friedrich TC; Wiehe K; O'Connor DH; Permar SR
    mBio; 2024 Mar; 15(3):e0316023. PubMed ID: 38349142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T Cell Responses Induced by Attenuated Flavivirus Vaccination Are Specific and Show Limited Cross-Reactivity with Other Flavivirus Species.
    Grifoni A; Voic H; Dhanda SK; Kidd CK; Brien JD; Buus S; Stryhn A; Durbin AP; Whitehead S; Diehl SA; De Silva AD; Balmaseda A; Harris E; Weiskopf D; Sette A
    J Virol; 2020 May; 94(10):. PubMed ID: 32132233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cross-reactive dengue virus-derived monoclonal antibodies to Zika virus envelope protein: Panacea or Pandora's box?
    Gunawardana SA; Shaw RH
    BMC Infect Dis; 2018 Dec; 18(1):641. PubMed ID: 30526531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mimotope discovery as a tool to design a vaccine against Zika and dengue viruses.
    Cuevas-Juárez E; Liñan-Torres A; Hernández C; Kopylov M; Potter CS; Carragher B; Ramírez OT; Palomares LA
    Biotechnol Bioeng; 2023 Sep; 120(9):2658-2671. PubMed ID: 37058415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Seroprevalence of Flavivirus Neutralizing Antibodies in Thailand by High-Throughput Neutralization Assay: Endemic Circulation of Zika Virus before 2012.
    Yamanaka A; Matsuda M; Okabayashi T; Pitaksajjakul P; Ramasoota P; Saito K; Fukasawa M; Hanada K; Matsuura T; Muramatsu M; Shioda T; Suzuki R
    mSphere; 2021 Aug; 6(4):e0033921. PubMed ID: 34259560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Longitudinal Analysis of Antibody Cross-neutralization Following Zika Virus and Dengue Virus Infection in Asia and the Americas.
    Montoya M; Collins M; Dejnirattisai W; Katzelnick LC; Puerta-Guardo H; Jadi R; Schildhauer S; Supasa P; Vasanawathana S; Malasit P; Mongkolsapaya J; de Silva AD; Tissera H; Balmaseda A; Screaton G; de Silva AM; Harris E
    J Infect Dis; 2018 Jul; 218(4):536-545. PubMed ID: 29618091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human antibodies to the dengue virus E-dimer epitope have therapeutic activity against Zika virus infection.
    Fernandez E; Dejnirattisai W; Cao B; Scheaffer SM; Supasa P; Wongwiwat W; Esakky P; Drury A; Mongkolsapaya J; Moley KH; Mysorekar IU; Screaton GR; Diamond MS
    Nat Immunol; 2017 Nov; 18(11):1261-1269. PubMed ID: 28945244
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Zika virus envelope protein glycan loop regulates virion antigenicity.
    Goo L; DeMaso CR; Pelc RS; Ledgerwood JE; Graham BS; Kuhn RJ; Pierson TC
    Virology; 2018 Feb; 515():191-202. PubMed ID: 29304471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A plant-produced vaccine protects mice against lethal West Nile virus infection without enhancing Zika or dengue virus infectivity.
    Lai H; Paul AM; Sun H; He J; Yang M; Bai F; Chen Q
    Vaccine; 2018 Mar; 36(14):1846-1852. PubMed ID: 29490880
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of Zika Virus Envelope Protein Domain III as a Target of Human Neutralizing Antibodies.
    Gallichotte EN; Young EF; Baric TJ; Yount BL; Metz SW; Begley MC; de Silva AM; Baric RS
    mBio; 2019 Sep; 10(5):. PubMed ID: 31530669
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.